FDA Modernization Act 2.0

Congress has passed the FDA Modernization Act 2.0 as part of the recent omnibus bill, removing the requirement to use animal testing in drug development. This allows drug companies to use alternative safety-testing models, such as cell-based assays, organ chips and microphysiological systems, and sophisticated computer modeling. Proponents state these alternatives are cost-effective and provide …

FDA Modernization Act 2.0 Read More »